{"protocolSection":{"identificationModule":{"nctId":"NCT01750788","orgStudyIdInfo":{"id":"16371"},"secondaryIdInfos":[{"id":"XA1205","type":"OTHER","domain":"Company internal"}],"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia","officialTitle":"Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study","acronym":"XANAP"},"statusModule":{"statusVerifiedDate":"2017-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-01-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2015-10-12","type":"ACTUAL"},"completionDateStruct":{"date":"2015-10-12","type":"ACTUAL"},"studyFirstSubmitDate":"2012-12-13","studyFirstSubmitQcDate":"2012-12-13","studyFirstPostDateStruct":{"date":"2012-12-17","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-09-20","lastUpdatePostDateStruct":{"date":"2017-09-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Stroke","Embolism","Atrial Fibrillation"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":2297,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.","armGroupLabels":["Group 1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Adjudicated major bleeding events","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"},{"measure":"Safety variables will be summarized using descriptive statistics based on adverse events collection","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"},{"measure":"All cause mortality","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"}],"secondaryOutcomes":[{"measure":"Adjudicated symptomatic thromboembolic events","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"},{"measure":"Non-major bleeding, collected as SAEs or non-serious AEs and defined as all bleeding events that do not fall in the category of major bleedings","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"},{"measure":"Treatment satisfaction as per patient assessment of rivaroxaban treatment by the physician at the final visit","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"},{"measure":"Healthcare resource","description":"Number of healthcare professional visits and hospitalizations due to anticoagulation","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"},{"measure":"Adverse events rates in the different AF risk factor categories","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"},{"measure":"Persistence with rivaroxaban treatment measured as percentage of patients on rivaroxaban treatment at 1 year after start of study treatment","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"},{"measure":"Reasons for switch of rivaroxaban treatment as per physician assessment during or at end of study","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"},{"measure":"Reasons for interruption of rivaroxaban treatment as per physician assessment during or at end of study","timeFrame":"after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS systemic embolism","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Many Locations","country":"Hong Kong"},{"city":"Many Locations","country":"India"},{"city":"Many Locations","country":"Indonesia"},{"city":"Many Locations","country":"Korea, Republic of"},{"city":"Many Locations","country":"Malaysia"},{"city":"Many Locations","country":"Pakistan"},{"city":"Many Locations","country":"Philippines"},{"city":"Many Locations","country":"Singapore"},{"city":"Many Locations","country":"Taiwan"},{"city":"Many Locations","country":"Thailand"},{"city":"Many Locations","country":"Vietnam"}]},"referencesModule":{"references":[{"pmid":"29976287","type":"DERIVED","citation":"Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ; Global XANTUS program Investigators. Global Prospective Safety Analysis of Rivaroxaban. J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M7474","name":"Embolism","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}